For definition of Groups, see Preamble Evaluation.
Supplement 7: (1987) (p. 344)
Chem. Abstr. Name: Pregn-4-ene-21-carboxylic acid,7-(acetylthio)-17-hydroxy-3-oxo-, g-lactone,(7a, 17a)
A. Evidence for carcinogenicity to humans (inadequate)
Cases of breast cancer have been reported in women who had used spironolactone. Four analytical studies, however, showed no consistent evidence of an assocation [ref: 1].
B. Evidence for carcinogenicity to animals (limited)
Spironolactone was tested by oral administration in two experiments in rats. Increased incidences of thyroid and testicular tumours were reported in one experiment but not in another experiment of longer duration with lower doses [ref: 1].
C. Other relevant data
No data were available to the Working Group.
Spironolactone is not classifiable as to its carcinogenicity to humans (Group 3).
For definition of the italicized terms, see Preamble Evaluation.
Subsequent evaluation: Vol. 79 (2001)
Also see previous evaluation: Vol. 24 (1980)
1. IARC Monographs, 24, 259-273, 1980
See Also: Toxicological Abbreviations Spironolactone (IARC Summary & Evaluation, Volume 24, 1980) Spironolactone (IARC Summary & Evaluation, Volume :79, 2001)